AGP Executive Report
Last update: 8 hours agoDiabetes Tech in Louisiana Spotlight: At ADA 2026 in New Orleans, Dexcom’s CONNECT trial reported clinically meaningful A1C drops for adults with type 2 diabetes not using insulin, strengthening the case for CGM in primary care. Next-Gen Obesity Drugs: ADA also highlighted phase 3 retatrutide results (TRANSCEND-T2D-1 and TRIUMPH-1), with major weight and A1C improvements plus benefits tied to knee osteoarthritis pain and obstructive sleep apnea. Diabetes Care Beyond Glucose: A major study presented at ADA warned infections should be treated as a “health hazard” for people with diabetes, calling for earlier prevention and management in guidelines. ADA Innovation Push: The American Diabetes Association named winners of its 2026 Innovation Challenge, including wearable biosensors and an AI-powered behavioral support platform. Local Tech & Education: Radiance Technologies Independence Bowl’s youth football clinic in Shreveport drew 300+ kids coached by current LA Tech players. Safety & Public Health: Louisiana drivers were warned about heat risks to items left in parked cars, including aerosol cans and temperature-sensitive medicines.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
